The Growth Suppressor PML Represses Transcription by Functionally and Physically Interacting with Histone Deacetylases

REFERENCES

• Adnane, J., Z. Shao, and P. D. Robbins. 1995. The retinoblastoma susceptibility gene product represses transcription when directly bound to the promoter. J. Biol. Chem. 270:8837–8843.
   PubMed Web of Science ®Google Scholar
• Ahn, J.-H., and G. S. Hayward. 1997. The major immediate-early proteins IE1 and IE2 of human cytomegalovirus colocalize with and disrupt PML-associated nuclear bodies at very early times in infected permissive cells. J. Virol. 71:4599–4613.
   PubMed Web of Science ®Google Scholar
• Ahn, J. H., E. J. Brignole, and G. S. Hayward. 1998. Disruption of PML subnuclear domains by the acidic IE1 protein of human cytomegalovirus is mediated through interaction with PML and may modulate a RING finger-dependent cryptic transactivator function of PML. Mol. Cell. Biol. 18:4899–4913.
   PubMedGoogle Scholar
• Alcalay, M., L. Tomassoni, E. Colombo, S. Stoldt, F. Grignani, M. Fagioli, L. Szekely, K. Helin, and P. G. Pelicci. 1998. The promyelocytic leukemia gene product (PML) forms stable complexes with the retinoblastoma protein. Mol. Cell. Biol. 18:1084–1093.
   PubMedGoogle Scholar
• Ayer, D. E., Q. A. Lawrence, and R. N. Eisenman. 1995. Mad-Max transcriptional repression is mediated by ternary complex formation with mammalian homologs of yeast repressor Sin3. Cell 80:767–776.
   PubMed Web of Science ®Google Scholar
• Bannister, A. J., and T. Kouzarides. 1996. The CBP co-activator is a histone acetyltransferase. Nature 384:641–643.
   PubMed Web of Science ®Google Scholar
• Boddy, M. N., K. Howe, L. D. Etkin, E. Solomon, and P. S. Freemont. 1996. PIC 1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukaemia. Oncogene 13:971–982.
   PubMed Web of Science ®Google Scholar
• Borrow, J., A. D. Goddard, D. Sheer, and E. Solomon. 1990. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science 249:1577–1580.
   PubMed Web of Science ®Google Scholar
• Braunstein, M., A. B. Rose, S. G. Holmes, C. D. Allis, and J. R. Broach. 1993. Transcriptional silencing in yeast is associated with reduced nucleosome acetylation. Genes Dev. 7:592–604.
   PubMed Web of Science ®Google Scholar
• Brehm, A., E. A. Miska, D. J. McCance, J. L. Reid, A. J. Bannister, and T. Kouzarides. 1998. Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 391:597–601.
   PubMed Web of Science ®Google Scholar
• Brown, D., S. Kogan, E. Lagasse, I. Weissman, M. Alcalay, P. G. Pelicci, S. Atwater, and J. M. Bishop. 1997. A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA 94:2551–2556.
   PubMed Web of Science ®Google Scholar
• Carmen, A. A., E. Stephen, S. E. Rundlett, and M. Grunstein. 1996. HDA1 and HDA3 are components of a yeast histone deacetylase (HDA) complex. J. Biol. Chem. 271:15837–15844.
   PubMedGoogle Scholar
• Chan, J. Y., L. Li, Y. H. Fan, Z. M. Mu, W. W. Zhang, and K. S. Chang. 1997. Cell-cycle regulation of DNA damage-induced expression of the suppressor gene PML. Biochem. Biophys. Res. Commun. 240:640–646.
   PubMed Web of Science ®Google Scholar
• Chang, K. S., Y. H. Fan, M. Andreeff, J. X. Liu, and Z. M. Mu. 1995. The PML gene encodes a phosphoprotein associated with the nuclear matrix. Blood 85:3646–3653.
   PubMed Web of Science ®Google Scholar
• Chang, K. S., S. A. Stass, D. T. Chu, L. L. Deaven, J. M. Trujillo, and E. J. Freireich. 1992. Characterization of a fusion cDNA (RARA/myl) transcribed from the t(15;17) translocation breakpoint in acute promyelocytic leukemia. Mol. Cell. Biol. 12:800–810.
   PubMed Web of Science ®Google Scholar
• Chen, G. Q., X. G. Shi, W. Tang, S. M. Xiong, J. Zhu, X. Cai, Z. G. Han, J. H. Ni, G. Y. Shi, P. M. Jia, M. M. Liu, K. L. He, C. Niu, J. Ma, P. Zhang, T. D. Zhang, P. Paul, T. Naoe, K. Kitamura, W. Miller, S. Waxman, Z. Y. Wang, H. de The, S. J. Chen, and Z. Chen. 1997. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL). I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 89:3345–3353.
   PubMed Web of Science ®Google Scholar
• De The, H., C. Lavau, A. Marchio, C. Chomienne, L. Degos, and A. Dejean. 1991. The PML-RARalpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 66:675–684.
   PubMed Web of Science ®Google Scholar
• Desbois, C., R. Rousset, F. Bantignies, and P. Jalinot. 1996. Exclusion of Int-6 from PML nuclear bodies by binding to the HTLV-I Tax oncoprotein. Science 273:951–953.
   PubMed Web of Science ®Google Scholar
• Doucas, V., A. M. Ishov, A. Romo, H. Juguilon, M. D. Weitzman, R. M. Evans, and G. G. Maul. 1996. Adenovirus replication is coupled with the dynamic properties of the PML nuclear structure. Genes Dev. 10:196–207.
   PubMed Web of Science ®Google Scholar
• Dyck, J. A., G. G. Maul, W. H. Miller, J. D. Chen, A. Kakizuka, and R. M. Evans. 1994. A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell 76:333–343.
   PubMed Web of Science ®Google Scholar
• Emiliani, S., W. Fischle, C. Van Lint, Y. Al-Abed, and E. Verdin. 1998. Characterization of a human RPD3 ortholog, HDAC3. Proc. Natl. Acad. Sci. USA 95:2795–2800.
   PubMed Web of Science ®Google Scholar
• Everett, R. D., and G. G. Maul. 1994. HSV-1 IE protein Vmw110 causes redistribution of PML. EMBO J. 13:5062–5069.
   PubMedGoogle Scholar
• Gongora, D., G. David, L. Pintard, C. Tissot, T. D. Hua, A. Dejean, and N. Mechti. 1997. Molecular cloning of a new interferon-induced PML nuclear body-associated protein. J. Biol. Chem. 272:19457–19463.
   PubMed Web of Science ®Google Scholar
• Grignani, F., S. De Matteis, C. Nervi, L. Tomassoni, V. Gelmetti, M. Cioce, M. Fanelli, M. Ruthardt, F. F. Ferrara, I. Zamir, C. Seiser, MA Lazar, S. Minucci, and P. G. Pelicci. 1998. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 391:815–818.
   PubMed Web of Science ®Google Scholar
• Grignani, F., P. F. Ferrucci, U. Testa, G. Talamo, M. Fagioli, M. Alcalay, A. Mencarelli, C. Peschle, I. Nicoletti, and P. G. Pelicci. 1993. The acute promyelocytic leukemia-specific PML-RARalpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 74:423–431.
   PubMed Web of Science ®Google Scholar
• Grignani, F., U. Testa, M. Fagioli, T. Barberi, R. Masciulli, G. Mariani, C. Peschle, and P. G. Pelicci. 1995. Promyelocytic leukemia-specific PML-retinoic acid alpha receptor fusion protein interferes with erythroid differentiation of human erythroleukemia K562 cells. Cancer Res. 55:440–443.
   PubMed Web of Science ®Google Scholar
• Grisolano, J. L., R. L. Wesselschmidt, P. G. Pelicci, and T. J. Ley. 1997. Altered myeloid development and acute leukemia in transgenic mice expressing PMLRARa under control of cathepsin G regulatory sequences. Blood 89:376–387.
   PubMed Web of Science ®Google Scholar
• Grunstein, M.. 1997. Histone acetylation in chromatin structure and transcription. Nature 389:349–352.
   PubMed Web of Science ®Google Scholar
• Guiochon-Mantel, A., F. J. Savouret, F. Quignon, K. Delaber, E. Milgrom, and H. de The. 1995. Effect of PML and PML-RAR on the transactivation properties and subcellular distribution of steroid hormone receptors. Mol. Endocrinol. 9:1791–1803.
   PubMedGoogle Scholar
• Hassig, C. A., J. K. Tong, T. C. Fleischer, T. Owa, P. G. Grable, D. E. Ayer, and S. L. Schreiber. 1998. A role for histone deacetylase activity in HDAC1-mediated transcriptional repression. Proc. Natl. Acad. Sci. USA 95:3519–3524.
   PubMedGoogle Scholar
• He, D., Z.-M. Mu, X. Le, J.-T. Hsieh, R.-C. Pong, L. W. K. Chung, and K.-S. Chang. 1997. Adenovirus-mediated expression of PML suppresses growth and tumorigenicity of prostate cancer cells. Cancer Res. 57:1868–1872.
   PubMed Web of Science ®Google Scholar
• He, L. Z., F. Guidez, C. Tribioli, D. Peruzzi, M. Ruthardt, A. Zelent, and P. P. Pandolfi. 1998. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat. Genet. 18:126–135.
   PubMed Web of Science ®Google Scholar
• He, L. Z., C. Tribioli, R. Rivi, D. Peruzzi, P. G. Pelicci, V. Soares, G. Cattoretti, and P. P. Pandolphi. 1997. Acute leukemia with promyelocytic features in PMLRARalpha transgenic mice. Proc. Natl. Acad. Sci. USA 94:5302–5307.
   PubMed Web of Science ®Google Scholar
• Kakizuka, A., W. H. J. Miller, K. Umesono, R. P. J. Warrell, S. R. Frankel, V. V. V. S. Murty, E. Dmitrovsky, and R. M. Evans. 1991. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARalpha with a novel putative transcription factor, PML. Cell 66:663–674.
   PubMed Web of Science ®Google Scholar
• Kamitani, T., K. Kito, H. P. Nguyen, H. Wada, T. Fukuda-Kamitani, and E. T. Yeh. 1998. Identification of three major sentrinization sites in PML. J. Biol. Chem. 273:26675–26682.
   PubMedGoogle Scholar
• Kamitani, T., H. P. Nguyen, K. Kito, T. Fukuda-Kamitani, and E. T. Yeh. 1998. Covalent modification of PML by the sentrin family of ubiquitin-like proteins. J. Biol. Chem. 273:3117–3120.
   PubMedGoogle Scholar
• Karlseder, J., H. Rotheneder, and E. Wintersberger. 1996. Interaction of Sp1 with the growth-and cell cycle-regulated transcription factor E2F. Mol. Cell. Biol. 16:1659–1667.
   PubMed Web of Science ®Google Scholar
• Koken, M. H. M., A. Reid, F. Quignon, M. K. Chelbi-Alix, J. M. Davies, J. H. S. Kabarowski, J. Zhu, S. Dong, S.-J. Chen, Z. Chen, C. C. Tan, J. Licht, S. Waxman, H. De Thé, and A. Zelent. 1997. Leukemia-associated retinoic acid receptor alpha fusion partners, PML and PLZF, heterodimerize and colocalize to nuclear bodies. Proc. Natl. Acad. Sci. USA 94:10255–10260.
   PubMed Web of Science ®Google Scholar
• Laherty, C. D., W. M. Yang, J. M. Sun, J. R. Davie, E. Seto, and R. N. Eisenman. 1997. Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression. Cell 89:349–356.
   PubMed Web of Science ®Google Scholar
• LaMorte, V. J., J. A. Dyck, R. L. Ochs, and R. M. Evans. 1998. Localization of nascent RNA and CREB binding protein with the PML-containing nuclear body. Proc. Natl. Acad. Sci. USA 95:4991–4996.
   PubMed Web of Science ®Google Scholar
• Le, X.-F., S. Vallian, Z.-M. Mu, M.-C. Hung, and K.-S. Chang. 1998. Recombinant PML adenovirus suppresses growth and tumorigenicity of human breast cancer cells by inducing G1 cell cycle arrest and apoptosis. Oncogene 16:1839–1849.
   PubMedGoogle Scholar
• Le, X. F., P. Yang, and K. S. Chang. 1996. Analysis of the growth and transformation suppressor domains of promyelocytic leukemia gene, PML. J. Biol. Chem. 271:130–135.
   PubMed Web of Science ®Google Scholar
• Lee, D. Y., J. J. Hayes, D. Pruss, and A. P. Wolffe. 1993. A positive role for histone acetylation in transcription factor access to nucleosomal DNA. Cell 72:73–84.
   PubMed Web of Science ®Google Scholar
• Li, H., C. Leo, J. Zhu, X. Wu, J. O'Neil, E-J. Park, and J. D. Chen. 2000. Sequestration and inhibition of Daxx-mediated transcription repression by PML. Mol. Cell. Biol. 20:1784–1796.
   PubMed Web of Science ®Google Scholar
• Lin, R. J., L. Nagy, S. Inoue, W. Shao, W. H. J. Miller, and R. M. Evans. 1998. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391:811–814.
   PubMed Web of Science ®Google Scholar
• Lin, S. Y., A. R. Black, D. Kostic, S. Pajovic, C. N. Hoover, and J. C. Azizkhan. 1996. Cell cycle-regulated association of E2F1 and Sp1 is related to their functional interaction. Mol. Cell. Biol. 16:1668–1675.
   PubMed Web of Science ®Google Scholar
• Liu, J. H., Z. M. Mu, and K. S. Chang. 1995. PML suppresses oncogenic transformation of NIH/3T3 cells by activated neu. J. Exp. Med. 181:1965–1973.
   PubMedGoogle Scholar
• Luo, R. X., A. A. Postigo, and D. C. Dean. 1998. Rb interacts with histone deacetylase to repress transcription. Cell 92:463–473.
   PubMed Web of Science ®Google Scholar
• Magnaghi-Jaulin, L., R. Groisman, P. Robin, S. Lorain, J. P. Le Villain, F. Troalen, D. Trouche, and B. Harel. 1998. Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature 391:601–605.
   PubMed Web of Science ®Google Scholar
• Mizzen, C. A., X. J. Yang, T. Kokubo, J. E. Brownell, A. J. Bannister, T. Owen-Hughes, J. Workman, L. Wang, S. L. Berger, T. Kouzarides, Y. Nakatani, and C. D. Allis. 1996. The TAF(II)250 subunit of TFIID has histone acetyltransferase activity. Cell 87:1261–1270.
   PubMed Web of Science ®Google Scholar
• Mu, Z. M., K. V. Chin, J. H. Liu, G. Lozano, and K. S. Chang. 1994. PML, a growth suppressor disrupted in acute promyelocytic leukemia. Mol. Cell. Biol. 14:6858–6867.
   PubMed Web of Science ®Google Scholar
• Mu, Z.-M., X.-F. Le, S. Vallian, A. B. Glassman, and K.-S. Chang. 1997. Stable overexpression of PML alters regulation of cell cycle progression in HeLa cells. Carcinogenesis 18:2063–2069.
   PubMedGoogle Scholar
• Muller, S., M. J. Matunis, and A. Dejean. 1998. Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J. 17:61–70.
   PubMed Web of Science ®Google Scholar
• Nagy, L., H. Y. Kao, D. Chakravarti, R. J. Lin, C. A. Hassig, D. E. Ayer, S. L. Schreiber, and R. M. Evans. 1997. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 89:373–380.
   PubMed Web of Science ®Google Scholar
• Ogryzko, V. V., R. L. Schiltz, V. Russanova, B. H. Howard, and Y. Nakatani. 1996. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87:953–959.
   PubMed Web of Science ®Google Scholar
• Pazin, M. J., and J. T. Kadonaga. 1997. What's up and down with histone deacetylation and transcription?. Cell 89:325–328.
   PubMed Web of Science ®Google Scholar
• Perez, A., P. Kastner, S. Sethi, Y. Lutz, C. Reibel, and P. Chambon. 1993. PMLRAR homodimers: distinct DNA binding properties and heteromeric interactions with RXR. EMBO J. 12:3171–3182.
   PubMed Web of Science ®Google Scholar
• Quignon, F., F. De Bels, M. Koken, J. Feunteun, J. C. Ameisen, and H. de The. 1998. PML induces a novel caspase-independent death process. Nat. Genet. 20:259–265.
   PubMedGoogle Scholar
• Shao, W., M. Fanelli, F. F. Ferrara, R. Riccioni, A. Rosenauer, K. Davison, W. W. Lamph, S. Waxman, P. G. Pelicci, C. F. Lo, G. Avvisati, U. Testa, C. Peschle, C. Gambacorti-Passerini, C. Nervi, and W. H. Miller Jr.. 1998. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J. Natl. Cancer Inst. 90:124–133.
   PubMed Web of Science ®Google Scholar
• Shen, Z. X., G. Q. Chen, J. H. Ni, X. S. Li, S. M. Xiong, Q. Y. Qiu, W. Tang, G. L. Sun, K. Q. Yang, Y. Chen, L. Zhou, Z. W. Fang, Y. T. Wang, J. Ma, P. Zhang, T. D. Zhang, S. J. Chen, Z. Chen, and Z. Y. Wang. 1997. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL). II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89:3354–3360.
   PubMed Web of Science ®Google Scholar
• Sherr, C. J.. 1994. G1 phase progression: cycling on cue. Cell 79:551–555.
   PubMed Web of Science ®Google Scholar
• Sternsdorf, T., K. Jensen, and H. Will. 1997. Evidence for covalent modification of the nuclear dot-associated proteins PML and Sp100 by PIC1/SUMO-1. J. Cell Biol. 139:1621–1634.
   PubMedGoogle Scholar
• Struhl, K.. 1998. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev. 12:599–606.
   PubMed Web of Science ®Google Scholar
• Szekely, L., K. Pokrovskaja, W.-Q. Jiang, H. de Thé, N. Ringertz, and G. Klein. 1996. The epstein-barr virus-encoded nuclear antigen ebna-5 accumulates in PML-containing bodies. J. Virol. 70:2562–2568.
   PubMedGoogle Scholar
• Torchia, J., D. W. Rose, J. Inostroza, Y. Kamei, S. Westin, C. K. Glass, and M. G. Rosenfeld. 1997. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature 387:677–684.
   PubMed Web of Science ®Google Scholar
• Vallian, S., J. Gaken, E. B. Gingold, T. Kouzarides, K. S. Chang, and F. Farzaneh. 1998. Regulation of Fos-mediated AP1 transcription by the promyelocytic leukemia protein. Oncogene 16:2843–2853.
   PubMedGoogle Scholar
• Vallian, S., K. V. Chin, and K. S. Chang. 1998. The promyelocytic leukemia protein interacts with Sp1 and inhibits its transactivation of the epidermal growth factor receptor promoter. Mol. Cell. Biol. 18:7147–7156.
   PubMedGoogle Scholar
• Vallian, S., J. A. Gaken, I. D. Trayner, E. B. Gingold, T. Kouzarides, K.-S. Chang, and F. Farzaneh. 1997. Transcriptional repression by the promyelocytic leukemia protein, PML. Exp. Cell Res. 237:371–382.
   PubMed Web of Science ®Google Scholar
• Vettese-Dadey, M., P. A. Grant, T. R. Hebbes, C. Crane, C. D. Allis, and J. L. Workman. 1996. Acetylation of histone H4 plays a primary role in enhancing transcription factor binding to nucleosomal DNA in vitro. EMBO J. 15:2508–2518.
   PubMed Web of Science ®Google Scholar
• Wade, P. A., and A. P. Wolffe. 1997. Histone acetyltransferases in control. Curr. Biol. 7:R82–R84.
   PubMedGoogle Scholar
• Wang, Z. G., L. Delva, M. Gaboli, R. Rivi, M. Giorgio, C. Cordon-Cardo, F. Grosveld, and P. P. Pandolfi. 1998. Role of PML in cell growth and the retinoic acid pathway. Science 279:1547–1551.
   PubMed Web of Science ®Google Scholar
• Wang, Z. G., R. Rivi, L. Delva, A. Konig, D. A. Scheinberg, P. Gambacorti, J. L. Gabrilove, R. P. J. Warrell, and P. P. Pandolfi. 1998. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner. Blood 92:1497–1504.
   PubMed Web of Science ®Google Scholar
• Wang, Z. G., D. Ruggero, S. Ronchetti, S. Zhong, M. Gaboli, R. Rivi, and P. P. Pandolfi. 1998. PML is essential for multiple apoptotic pathways. Nat. Genet. 20:266–272.
   PubMed Web of Science ®Google Scholar
• Warrell, R. P. J., S. R. Frankel, W. H. J. Miller, D. A. Scheinberg, L. M. Itri, W. N. Hittelman, R. Vyas, M. Andreeff, A. Tafuri, A. Jakubowski, et al.. 1991. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N. Engl. J. Med. 324:1385–1393.
   PubMed Web of Science ®Google Scholar
• Weis, K., S. Rambaud, C. Lavau, J. Jansen, T. Carvalho, M. Carmo-Fonseca, A. Lamond, and A. Dejean. 1994. Retinoic acid regulates aberrant nuclear localization of PML-RARalpha in acute promyelocytic leukemia cells. Cell 76:345–356.
   PubMed Web of Science ®Google Scholar
• Yang, W. M., Y. L. Yao, J. M. Sun, J. R. Davie, and E. Seto. 1997. Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family. J. Biol. Chem. 27:28001–28007.
   Google Scholar
• Yoshida, H., K. Kitamura, K. Tanaka, S. Omura, T. Miyazaki, T. Hachiya, R. Ohno, and T. Naoe. 1996. Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway. Cancer Res. 56:2945–2948.
   PubMed Web of Science ®Google Scholar